Collegium Pharmaceutical Stock Working Capital
| COLL Stock | USD 30.71 0.48 1.54% |
Collegium Pharmaceutical fundamentals help investors to digest information that contributes to Collegium Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Collegium Stock. The fundamental analysis module provides a way to measure Collegium Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Collegium Pharmaceutical stock.
| Last Reported | Projected for Next Year | ||
| Net Working Capital | 79.7 M | 45 M | |
| Change In Working Capital | 21.7 M | 22.8 M |
Collegium | Working Capital |
Collegium Pharmaceutical Company Working Capital Analysis
Collegium Pharmaceutical's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Collegium Pharmaceutical Working Capital | 79.69 M |
Most of Collegium Pharmaceutical's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Collegium Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Collegium Working Capital Driver Correlations
Understanding the fundamental principles of building solid financial models for Collegium Pharmaceutical is extremely important. It helps to project a fair market value of Collegium Stock properly, considering its historical fundamentals such as Working Capital. Since Collegium Pharmaceutical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Collegium Pharmaceutical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Collegium Pharmaceutical's interrelated accounts and indicators.
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Collegium Capital Surpluse
Capital Surpluse |
|
In accordance with the company's disclosures, Collegium Pharmaceutical has a Working Capital of 79.69 M. This is 81.28% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The working capital for all United States stocks is 94.61% higher than that of the company.
Collegium Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Collegium Pharmaceutical's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Collegium Pharmaceutical could also be used in its relative valuation, which is a method of valuing Collegium Pharmaceutical by comparing valuation metrics of similar companies.Collegium Pharmaceutical is currently under evaluation in working capital category among its peers.
Collegium Pharmaceutical Current Valuation Drivers
We derive many important indicators used in calculating different scores of Collegium Pharmaceutical from analyzing Collegium Pharmaceutical's financial statements. These drivers represent accounts that assess Collegium Pharmaceutical's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Collegium Pharmaceutical's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 688.5M | 689.2M | 652.6M | 1.0B | 934.7M | 981.4M | |
| Enterprise Value | 540.1M | 781.7M | 724.9M | 1.5B | 1.3B | 1.4B |
Collegium Pharmaceutical ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Collegium Pharmaceutical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Collegium Pharmaceutical's managers, analysts, and investors.Environmental | Governance | Social |
Collegium Fundamentals
| Return On Equity | 0.43 | ||||
| Return On Asset | 0.0968 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | 0.35 % | ||||
| Current Valuation | 1.76 B | ||||
| Shares Outstanding | 32.25 M | ||||
| Shares Owned By Insiders | 1.64 % | ||||
| Shares Owned By Institutions | 98.36 % | ||||
| Number Of Shares Shorted | 6.21 M | ||||
| Price To Earning | 28.80 X | ||||
| Price To Book | 4.29 X | ||||
| Price To Sales | 1.68 X | ||||
| Revenue | 566.77 M | ||||
| Gross Profit | 345.74 M | ||||
| EBITDA | 308.33 M | ||||
| Net Income | 48.16 M | ||||
| Cash And Equivalents | 122.72 M | ||||
| Cash Per Share | 3.60 X | ||||
| Total Debt | 674.28 M | ||||
| Debt To Equity | 3.82 % | ||||
| Current Ratio | 0.99 X | ||||
| Book Value Per Share | 7.27 X | ||||
| Cash Flow From Operations | 274.75 M | ||||
| Short Ratio | 15.69 X | ||||
| Earnings Per Share | 2.34 X | ||||
| Target Price | 42.25 | ||||
| Number Of Employees | 197 | ||||
| Beta | 0.95 | ||||
| Market Capitalization | 1.01 B | ||||
| Total Asset | 1.14 B | ||||
| Retained Earnings | (233.19 M) | ||||
| Working Capital | 79.69 M | ||||
| Current Asset | 96.88 M | ||||
| Current Liabilities | 8.43 M | ||||
| Net Asset | 1.14 B |
About Collegium Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Collegium Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Collegium Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Collegium Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Collegium Pharmaceutical Piotroski F Score and Collegium Pharmaceutical Altman Z Score analysis. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.49) | Earnings Share 2.34 | Revenue Per Share 18.538 | Quarterly Revenue Growth 0.165 | Return On Assets 0.0968 |
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.